CPPF, A Novel Microtubule Targeting Anticancer Agent, Inhibits the Growth of a Wide Variety of Cancers

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Microtubule targeting agents (MTAs) are vital anticancer drugs, but drug resistance limits their efficacy.
• Developing novel MTAs is crucial to overcome resistance and improve cancer treatment outcomes.

Purpose of the Study:

• To report the discovery and preclinical evaluation of a novel microtubule targeting agent, 5-(3-chlorophenyl)-N-(3-pyridinyl)-2-furamide (CPPF).
• To assess CPPF's efficacy against various cancer cell lines, including multidrug-resistant ones, and its in vivo anticancer activity and toxicity.

Main Methods:

• CPPF efficacy was evaluated in 2D and 3D cancer cell culture systems.
• In vivo studies utilized mouse xenograft and two-step skin cancer models, alongside zebrafish toxicity models.
• Mechanism of action was investigated through microtubule depolymerization, mitotic arrest, and apoptosis assays.

Main Results:

• CPPF suppressed proliferation in diverse cancer cell lines, including those resistant to paclitaxel and colchicine.
• The agent induced depolymerization of microtubules, leading to mitotic arrest and apoptosis.
• In vivo studies confirmed anticancer effects in mouse models, with low observed toxicity in zebrafish.

Conclusions:

• CPPF demonstrates significant anticancer potential by targeting microtubules and overcoming drug resistance.
• Its efficacy in preclinical models and favorable safety profile suggest CPPF could be a promising chemotherapeutic drug.